BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advances Personalized Immunotherapy Technology Targeting Advanced Breast Cancer Patients
Completed development of novel, frozen formulation of Bria-IMT for on-demand shipment to clinical sites New formulation to accommodate higher patient volumes at reduced per-dose costs Mechanism of action and proof of concept achieved in FDA-approved clinical trial with advanced breast cancer patients The global cancer immunotherapy market is expected to be valued at nearly $125 billion by the end of 2024 Breast cancer remains one of the most commonly diagnosed cancers among women globally, with 2.1 million cases expected in 2018 Battling a cancer prognosis is often referred to as “fighting the good fight,” but it’s a tough, uphill battle…